Suppr超能文献

Sofotec Novolizer与慢性阻塞性肺疾病(COPD)和哮喘领域现有标准设备的治疗等效性。

Therapeutic equivalence of the Sofotec Novolizer to established standard devices in COPD and asthma.

作者信息

Kunkel G, Chuchalin A G

机构信息

Allergy and Asthma Clinic, Charité, Campus Virchow, Humboldt University, Berlin, Germany.

出版信息

Curr Opin Pulm Med. 2001 Apr;7 Suppl 1:S15-7.

Abstract

The Novolizer is a breath-actuated multidose dry powder inhaler that was developed as an alternative to the pressurized metered dose inhalers. The efficacy, safety and tolerability of the Novolizer has been compared with those of established inhalational devices for the delivery of salbutamol (Sultanol) in patients with chronic obstructive pulmonary disease and for the administration of budesonide (Pulmicort Turbuhaler) to patients with asthma. In both studies, improvement in forced expiratory volume in 1 s in patients who were randomly assigned to use the Novolizer was comparable with that in patients who used the established devices. Furthermore, no differences in tolerability or safety between the Novolizer and the control devices were observed. Finally, patient acceptance of the Novolizer was high, with the majority of patients who used it stating that they would use the device again.

摘要

诺沃利泽是一种呼吸驱动的多剂量干粉吸入器,它是作为压力定量吸入器的替代品而开发的。已将诺沃利泽与已有的吸入装置在慢性阻塞性肺疾病患者中递送沙丁胺醇(舒喘灵)以及在哮喘患者中给予布地奈德(普米克都保)的疗效、安全性和耐受性进行了比较。在两项研究中,随机分配使用诺沃利泽的患者1秒用力呼气量的改善情况与使用已有的装置的患者相当。此外,未观察到诺沃利泽与对照装置在耐受性或安全性方面存在差异。最后,患者对诺沃利泽的接受度很高,大多数使用过它的患者表示会再次使用该装置。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验